A single amino acid change in murine norovirus NS1/2 is sufficient for colonic tropism and persistence

Timothy J. Nice, David W. Strong, Broc T. McCune, Calvin S. Pohl, Herbert W. Virgin#

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis Missouri 631101

#Corresponding author:
Department of Pathology and Immunology, Box 8118, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110. Phone: (314) 362-9223. Fax: (314) 362-4096. E-mail: virgin@wustl.edu.

Running Title: NS1/2 determines MNV tropism and persistence

Abstract word count: 167

Manuscript word count: 4,289
Abstract

Human norovirus (HuNoV) is the major cause of acute non-bacterial gastroenteritis worldwide but has no clear animal reservoir. HuNoV can persist after the resolution of symptoms and this persistence may be essential for viral maintenance within the population. Many strains of the related murine norovirus (MNV) also persist, providing a tractable animal model for studying norovirus (NoV) persistence. We have used recombinant cDNA clones of representative persistent (CR6) and non-persistent (CW3) strains to identify a domain within the non-structural gene NS1/2 that is necessary and sufficient for persistence. Furthermore, we found that a single aspartic acid to glutamic acid change in CW3 NS1/2 was sufficient for persistence. This same conservative change also caused increased growth of CW3 in the proximal colon, which we found to be a major tissue reservoir of MNV persistence, suggesting that NS1/2 determines viral tropism necessary for persistence. These findings represent the first identified function for NoV NS1/2 during infection and establish a novel model system for the study of enteric viral persistence.
Introduction

Human noroviruses (HuNoVs) are the leading cause of non-bacterial gastroenteritis and a significant public health problem worldwide, causing both outbreaks and sporadic cases of acute gastrointestinal disease [Reviewed in (3, 18, 45)]. There is no evidence for an animal reservoir of HuNoV, suggesting that asymptomatic shedding within the human population could initiate symptomatic infection. Indeed, PCR-based detection has shown that HuNoVs are present in asymptomatic individuals within a variety of communities and ranges in prevalence from 3-13% (5, 10, 16, 43). Furthermore, experimental infection of volunteers revealed that some individuals continue to shed virus for up to weeks after the resolution of symptoms (4), and there are examples where outbreaks likely originated with asymptomatic HuNoV shedders (9, 47, 53). Taken together, these studies demonstrate that asymptomatic and persistent infections are an important aspect of HuNoV biology. However, the molecular mechanisms of NoV persistence remain incompletely understood.

Noroviruses (NoVs) are positive sense single-stranded RNA viruses in the calicivirus family. They are classified into five genetic groups (genogroups) with HuNoVs in genogroups I, II, and IV (GI, GII, and GIV), bovine noroviruses in GIII, and murine noroviruses (MNV) in GV (60). The NoV genome is ~7.5 kb in length and encodes three open reading frames (ORFs) (28) with an additional ORF4 in MNV (36, 55). ORF1 encodes the NoV non-structural polyprotein which is cleaved into six mature peptides (NS1/2 and NS3 through NS7) by the ORF1-encoded viral protease NS6 (11, 34, 50). ORF2 encodes the major structural
protein (VP1), which self-assembles into the icosahedral viral capsid (27), and ORF3 encodes a minor structural protein (VP2) (21). MNV ORF4 is an alternate reading frame within ORF2 and encodes virulence factor 1 (VF1) (36). NS1/2 is the most N-terminal viral protein encoded by ORF1. The cleavage site between NS1/2 and NS3 has been confirmed by mutagenesis studies and the position of this cleavage is conserved among all NoVs. All genera of caliciviruses other than NoVs have an additional viral protease cleavage site within the region homologous to NS1/2 resulting in two mature viral proteins derived from this region (37, 41, 51). It is possible that some NoVs have lost this cleavage event, but there is one report of additional cleavage of the human NS1/2 protein in cells transfected with HuNoV ORF1 (49) and MNV NS1/2 can be cleaved by caspase 3 (50). NS1/2 localizes to organelles in the secretory pathway (20, 24) and HuNoV NS1/2 disrupts protein secretion in transfected cells (19, 20). However, very little is known about the function of NS1/2 in NoV replication or pathogenesis. Similar to HuNoV, MNV establishes persistent asymptomatic infection (23, 55) and therefore represents an ideal model system in which to study NoV persistence. While most strains of MNV persist, the strain MNV1 is cleared. MNV1 was identified as a cause of lethality in RAG/STAT1 knockout mice (31) and it was passaged intracranially (I.C.) in these mice until a culture system was established (59). While MNV1 rapidly kills STAT1 knockout mice, it persists avirulently in RAG knockout mice and is cleared from immune-sufficient mice (31, 52). Subsequently, many closely related strains of MNV isolated from stool
samples were shown to persist in immune-sufficient mice (23, 55). One of these persistent stool isolates, CR6, has been shown to be avirulent in STAT1 knockout mice, demonstrating a second phenotypic distinction with MNV1 (52). A reverse genetics system for MNV exists (58), making phenotypic analyses of MNV1 and persistent strains possible (7, 36, 52, 54). The increased virulence of MNV1 has been linked to the protruding domain of the capsid gene (7, 52), but the gene responsible for MNV persistence has not been identified.

Herein, we used recombinant cDNA clones of the non-persistent strain MNV1.CW3 (subsequently referred to as CW3) and persistent strain CR6 to identify a genetic determinant of persistence. In contrast to virulence in STAT1 knockout mice (52), reciprocal replacement of the capsid gene did not alter persistence. Instead, the NS1/2 gene of CR6 enabled persistence of CW3. Within NS1/2, we further narrowed the determinant of persistence to the 5’ domain and to a single amino acid within this domain. Furthermore, this same determinant increased growth of CW3 in the proximal colon, a major reservoir of CR6 persistence. This is the first demonstrated function for NS1/2 during infection and the first report of a protein other than the MNV capsid to alter viral tropism. This is also the first study identifying a genetic determinant for enteric viral persistence.
Materials and Methods

Generation of recombinant MNV stocks

Construction of molecular clones of CW3 (EF014462.1) and CR6 (JQ237823) and the strategy for cloning of viral gene substitutions has been previously described (52). Primers used for the substitutions of NS1/2 5’ and 3’ domains were “NS1/2 forward” 5’-GTGAATGAGGATGGCAACGCCATCTTC-3’, “5’ NS1/2 reverse” 5’-GCGTCCTCCGATGGGAGGGCC-3’, “3’ NS1/2 forward” 5’-GCGCCCTCCCATGCGGAGGAC-3’ and “CR6 3’ NS1/2 reverse” 5’-AGGTCGAAGGGCCCTTCGGCCTGCCA-3’.

Generation of viral stocks from MNV-encoding plasmids was performed as described (52) with minor modifications. Briefly, plasmids were transfected into 293T cells with TransIT-LT1 (Mirus Bio, Madison WI) and virus was recovered 48 hours post-transfection by freezing and thawing. Clarified 293T supernatants were passaged one to two times on RAW264.7 cells at a multiplicity of infection (MOI) of ≤0.05 and virus was recovered 48 hours post-infection. Virus-containing RAW264.7 cell supernatants were cleared of debris by centrifugation for two minutes at ≥18000g. All viral stocks were derived from cDNA clones rather than serially passaged MNV isolates.

Mice and infections

C57BL/6 mice (stock #000664) were purchased from Jackson Laboratories (Bar Harbor, ME) and housed at Washington University School of Medicine under specific pathogen free conditions (13) according to university
guidelines. Cages of male or female mice were inoculated with virus at six to eight weeks of age by the per-oral route in a volume of 25-35 µL. A dose of $3 \times 10^4$ plaque forming units (PFU) was used for all experiments with one exception (Fig. 5E, $1 \times 10^6$ PFU).

Stool and tissues were harvested into 2mL tubes (Sarstedt, Germany) with 1mM diameter zirconia/silica beads (Biospec, Bartlesville, OK). Tissues were flash frozen in a bath of ethanol and dry ice and either processed on the same day or stored at -80°C.

**Plaque assay**

Culture of RAW264.7 and plaque assay for determining titer of virus stocks was performed as described (52). Growth curve plaque assays utilized suspension-adapted RAW264.7 cells maintained in MEM supplemented with 10% bovine serum, 1% non-essential amino acids, 100 µg/ml penicillin-streptomycin, 2 mM L-glutamine, 10 mM HEPES and 0.225% sodium bicarbonate. RAW264.7 cells were plated on six-well plates at a density of $2 \times 10^6$ cells per well. 16-24 hours later, medium was removed and 10-fold serial dilutions of virus inoculum were added in 500 µL per well. Plates were incubated for 1 hour at room temperature on a rocking platform before removing the inoculum and overlaying the cells with 2 ml per well of 1% Methylcellulose in MEM supplemented with 10% fetal calf serum, 100 µg/ml penicillin-streptomycin, 2 mM L-glutamine, 10 mM HEPES. Plates were incubated at 37 degrees for
three to four days and plaques were visualized by staining with 0.2% crystal violet and 20% ethanol.

Quantitative RT-PCR

RNA from stool was isolated using either RNeasy Miniprep (Qiagen, Valencia CA) or Quick-RNA Miniprep (Zymo Research, Irvine CA) kits. RNA from tissues was isolated using Trizol (Life Technologies, Carlsbad CA) according to the manufacturer’s protocol. Five µL of RNA from stool or 1 µg of RNA from tissue were used as a template for cDNA synthesis with the ImPromII reverse transcriptase system (Promega, Madison WI). When evident in the melt curve analysis, DNA contamination was removed using the DNAfree kit (Life Technologies).

MNV TaqMan was performed as described (6). MNV genome quantities from tissue samples were normalized to the housekeeping gene, ribosomal protein S29 (RPS29). SYBR green qPCR for RPS29 was performed with the forward primer 5’-AGCAGCTCTACTGGAGTCACC-3’ and reverse primer 5’-AGGTCGCTTAGTCCAACTTAATG-3’ at a concentration of 0.2 µM in 1x Power SYBR Green Master Mix (Life Technologies). Cycling parameters were identical to MNV TaqMan with the exception of an additional melt curve analysis.

Statistical analysis

Data were analyzed with Prism 5 software (GraphPad Software, San Diego CA). In all graphs, *** = p<0.001, ** = p<0.01, * = p<0.05, and n.s. = not significant.
significant (p>0.05) determined by one-way ANOVA with Tukey’s posttest (single
time-point experiments) or two-way ANOVA with Bonferroni’s posttest (kinetic
experiments). All error bars depict standard error of the mean.
Results

CW3 and CR6 differ in quantity and persistence of shedding in stool.

Molecular clones of the representative non-persistent and persistent strains CW3 and CR6 were used for a kinetic comparison of fecal shedding. CR6 was shed by six out of eight mice on day three and reached a peak level of shedding by day seven post-infection. The day seven shedding of CW3 was significantly lower than CR6 and CW3 was not detected in more than 50% of mice at any time-point. Average CW3 shedding decreased below the limit of detection at day 14 and remained undetectable at days 21 and 35 (Fig. 1). In contrast, CR6 was consistently shed between days 21 and 70 with no observed clearance in any animals (Fig. 1). Therefore, CR6 infection leads to long-lived persistent shedding as well as significantly greater shedding than CW3 during acute infection.

MNV capsid does not determine persistence.

VP1 was a likely candidate for determining MNV persistence due to its role in immunity, lethality, and tropism (7, 14, 15, 52, 54). Therefore, we assessed the shedding of viruses with reciprocal substitutions in the VP1 gene (including the overlapping VF1 gene as depicted in figure 2A). The number of genome copies in the stool at 35 days post-infection was not significantly different between CW3 and CW3 encoding the VP1 gene from CR6 (CW3-VP1) or between CR6 and CR6 encoding the VP1 gene from CW3 (CR6-VP1) (Fig.
These data indicate that a gene or genes other than VP1 are required for persistent infection by MNV. The 5' region of the NS1/2 gene is necessary and sufficient for persistence. To determine whether a CR6 gene other than VP1 was sufficient to enable CW3 persistence, we tested additional CW3 viruses with single CR6-derived gene replacements [Fig. 2A, (52)]. A comparison of threshold cycle (Ct) values revealed that shedding of CW3-NS1/2 was significantly greater than all other single-gene substitutions (Fig. 2C). To confirm and quantify the result of this screen, we generated two additional viral stocks of CW3-NS1/2 and tested all three stocks for persistent shedding. All three biological replicates of CW3-NS1/2 were detected in stool at 35 days post-infection and the quantity of MNV genomes was not significantly different from that of CR6 (Fig. 2D). The reciprocal substitution of NS1/2 from CW3 into CR6 did not generate virus and could not be tested for persistence. These findings indicate that the NS1/2 gene of CR6 is sufficient to enable CW3 persistence. The NS1/2 gene encodes a 3' domain conserved among NoVs (1) and a 5' domain that is more divergent. To narrow the persistence determinant to a single domain, we generated CW3 with the 5' domain of CR6 NS1/2 (CW3-5' NS1/2) and CW3 with the 3' domain of CR6 NS1/2 (CW3-3' NS1/2) as depicted in figure 2A. While persistent CW3-3' NS1/2 shedding was not detected, CW3-5' NS1/2 shedding was indistinguishable from that of CR6 (Fig. 2E) To test whether the 5' NS1/2 domain was also necessary for persistence, we generated CR6 with
a CW3 substitution in the 5’ domain of the NS1/2 gene (CR6-5’ NS1/2).

Persistent shedding of CR6-5’ NS1/2 was significantly lower than CR6 and not significantly different than CW3 (Fig. 2E). Taken together, these data demonstrate that the 5’ domain of the NS1/2 gene is necessary and sufficient for MNV persistence.

An aspartic acid to glutamic acid change at amino acid 94 of NS1/2 is sufficient for persistence

CR6 is one of seven persistent strains identified to date (23, 55). To test whether CW3 has unique polymorphisms that correlate with its inability to persist, we compared the 5’ domain of NS1/2 from CW3 and the seven persistent MNV strains (Fig. 3A). Amino acid alignment showed that only a single residue was both unique to CW3 and conserved among the persistent strains of MNV. This difference was a conservative change at amino acid 94, with glutamic acid present in persistent strains and aspartic acid present in CW3 (Fig. 3A). To assess whether this difference was involved in determining persistence, we generated a mutant of CW3 that encoded the conserved glutamic acid present in CR6 (CW3D94E). Additionally, we made the reciprocal mutation in CR6, changing the conserved glutamic acid to an aspartic acid (CR6E94D). CR6 persistent shedding was not significantly changed by the E94D mutation (Fig. 3B) and sequencing demonstrated no reversion to E94 in vivo (data not shown). In contrast, CW3 shedding was significantly increased by the D94E mutation to levels that were not significantly different from CR6 (Fig. 3B). Furthermore, a
D94E mutation in the non-persistent CR6-5'NS1/2 chimera rescued its ability to persist. This striking result demonstrates that glutamic acid at amino acid 94 of NS1/2 is sufficient, though not necessary, for persistence.

Persistent and non-persistent viruses have similar in vitro growth

The association of NS1/2 with cellular membranes and the viral replication complex (25) suggested that it may have a role in viral replication that is altered by the persistence determinant. To test this hypothesis, we compared in vitro growth of the persistent viruses CW3D94E and CR6 with the non-persistent viruses CW3 and CR6-5' NS1/2. Infection of RAW264.7 cells at an MOI of 5 revealed no significant overall difference in growth at any time post-infection between any pair of persistent and non-persistent viruses (Fig. 4). At an MOI of 0.05 there were also no significant differences other than at four hours post-infection between CR6 and CR6-5' NS1/2 (p<0.05, Fig. 4). However, there were no differences between CW3 and CW3D94E at any time that would indicate a role for this early growth difference in determining the persistence phenotype. Together, these data show that the persistence determinant has little to no effect on in vitro growth in RAW264.7 cells.

CR6 grows better than CW3 in the proximal colon

While no growth difference was seen in RAW264.7 cells, the significant difference in fecal shedding between CW3 and CR6 on day seven (Fig. 1) suggested that there was a difference in enteric growth during the early stages of
infection in vivo. To identify the preferential enteric site(s) of CR6 replication, relative levels of persistent CR6 were measured in anatomically distinct regions along the gastrointestinal (GI) tract. CR6 was detected in the proximal colon at levels significantly greater than all other GI regions with the exception of the cecum (Fig. 5A). This observation was supported by recent publications which also predominantly detected persistent MNV strains in the cecum and/or proximal colon (2, 54).

Therefore, the proximal colon was included as the representative enteric tissue in a comparison between CR6 and CW3 growth during acute infection. Spleen and mesenteric lymph node (MLN) were also included in the comparison because MNV grows in macrophages and dendritic cells (DCs) and can spread to these tissues. The peak titer of both strains in all tissues was reached by day seven (Fig. 5B). In the proximal colon, CR6 grew significantly better than CW3 from day three through 14 and CW3 was only minimally detected at any time-point (Fig. 5B, left panel). In the spleen, CW3 grew significantly better than CR6 between days three and seven, but was cleared by day 14 (Fig. 5B, middle panel). This difference in the spleen was in accordance with recent publications demonstrating the ability of CW3 and MNV1 to spread systemically (29, 52) and indicates that the failure of CW3 to persist in the intestine is not due to a failure to establish infection. Both strains were detected in the MLN with no significant difference before day 14 when CW3 was cleared (Fig. 5B, right panel). Taken together, these data demonstrate significant differences in tissue tropism.
between CW3 and CR6 in the spleen and proximal colon, the latter being a major site of persistence.

**NS1/2 amino acid 94, rather than capsid, determines growth in the proximal colon**

Other studies have mapped MNV1 tropism changes to VP1 (52, 54), so we used CW3-VP1 and CR6-VP1 to test the role of VP1 in determining the tropism differences revealed in figure 5B. Growth of CW3-VP1 in the proximal colon seven days after infection was not significantly higher than CW3 and growth of CR6-VP1 was not significantly lower than CR6 (Fig. 5C, left panel). In the spleen, growth of CW3-VP1 was significantly lower than CW3 and not significantly different from CR6; CR6-VP1 was significantly higher than CR6 and not significantly different from CW3 (Fig. 5C, middle panel). Therefore, VP1 determines CW3 tropism for the spleen but not CR6 tropism for the proximal colon.

In parallel, we tested day seven growth of NS1/2 mutants to address the effect of the persistence determinant on tropism during acute infection. The persistent viruses CW3-NS1/2 and CW3D94E grew in both the spleen and proximal colon at levels significantly higher than the non-persistent CR6-5’ NS1/2 which was not detected in any tissue (Fig. 5D). Strikingly, introduction of the D94E mutation into CR6-5’ NS1/2 resulted in significantly increased growth in the colon without a significant change in the spleen (Figure 5D, CR6-5’ NS1/2D94E).
Therefore, D94E is sufficient for growth in the proximal colon, but not in the spleen, during acute infection.

MNV persistence is restricted to the intestine

The correlation between persistent fecal shedding and growth in the proximal colon during acute infection (Figs. 2E, 3B, and 5D) raised the possibility that MNV persistence is an intestine-specific phenotype. CR6 did not persist outside of the intestine and associated lymphoid tissue, but its replication during acute infection was also restricted to these same sites (Fig. 5B and not shown). Therefore, we took advantage of the expanded tropism of CR6-VP1 during acute infection to test this hypothesis. On day three post-infection with 1x10⁶ PFU, CR6-VP1 had grown in both enteric tissues (Fig. 5E, proximal colon and MLN) as well as systemic tissues (Fig. 5E, Spleen and Liver). However, while CR6-VP1 was still present in the intestine on day 35, it was reduced to the limit of detection in the spleen and liver (Fig. 5E). This result shows that MNV persistence is specific to the intestine and provides a possible explanation for the correlation between enteric growth during acute infection and persistence.
The findings presented here demonstrate that the 5' domain of NS1/2 is necessary and sufficient for MNV persistence. Furthermore, a single conservative change from aspartic acid to glutamic acid at amino acid 94 within this domain is sufficient for CW3 to persist. This D94E change also determines tropism for the proximal colon but not the spleen during acute infection. Notably, the proximal colon is a major site of MNV persistence, while the spleen does not support persistent replication.

MNV as a model of persistent enteric viral infection

There is no clear animal reservoir for HuNoV suggesting that it has other adaptations for viral maintenance between outbreaks. Asymptomatic and persistent shedding is likely to be one way that HuNoVs are maintained (5, 10, 16, 43, 53), yet many questions remain about the mechanism of NoV persistence. Furthermore, while asymptomatic shedding has been demonstrated for many enteric viruses (17, 35, 44), a tractable model has not been established in which to study enteric persistence. We have characterized a novel model of persistence and identified the first genetic determinant of enteric persistence. Future study using the MNV model system has the exciting potential to reveal general principles of enteric persistence and host-pathogen interactions in the intestine.

Relationship between enteric growth and persistence
We have shown a correlation of persistent shedding with growth in the colon, but not the spleen, during acute infection (Figs. 2E, 3B, and 5D). This correlation suggests that efficient colonic replication is required for persistence. Support for this idea comes from the fact that CR6-VP1, which has broad early tissue tropism, persists in the colon and MLN but not systemic sites (Fig. 5E). Therefore, efficient early replication in colon may correlate with persistence because MNV persistence is restricted to enteric tissues. The importance of enteric growth may reflect a requirement for fecal shedding and re-exposure, replication in enteric cell types, or induction of enteric immune responses. CR6 infection results in increased fecal shedding compared to CW3 (Fig. 1). Consequently, there are likely an increased number of virions in the environment and more frequent re-exposure of the intestinal epithelium. Antigenic drift within a cage may increase exposure to viral mutations that outpace immune elimination and result in persistence. Sequencing of CW3D94E from persistently infected mice reveals that mutations in the protruding domain of the capsid are in fact present (TJN, data not shown). Furthermore, there is evidence that this type of selection takes place in human populations and is important for persistence of HuNoV (33). It is notable that infection with 3x10^7 PFU of CW3, rather than the 3x10^4 PFU used here, results in appreciable shedding in the stool during acute infection and yet is ultimately cleared (13). Therefore, while it is still possible that CR6 and other persistent strains have a unique ability to promote antigenic drift, re-exposure to shed MNV per se is not likely to be sufficient to explain the capacity to persist.
A separate, but not mutually exclusive, hypothesis to explain the importance of enteric growth is that characteristics of the immune system unique to this anatomical location are critical for persistence. The mammalian mucosal immune system has evolved in proximity to abundant commensal microbes and has a unique requirement for regulatory mechanisms that prevent excessive inflammatory responses to these microbes (22, 26, 32, 39, 56). These mechanisms include both intestine-specific differentiation programs for innate leukocytes (38, 48) and the related ability to generate regulatory T cell responses (40). An analogous regulatory immune response may be required for tolerance of persistent MNV in the intestine. Alternatively, because MNV is known to replicate in macrophages and dendritic cells (59), the unique differentiation states of these cell types in the intestine may provide cell-intrinsic growth requirements for persistent replication. Clarification of the anatomical requirements for MNV persistence will provide complementary insights to molecular studies of NS1/2 in establishing the mechanism of persistence in this novel model system.

**Potential mechanisms of NS1/2 in persistence**

Studies implicating NS1/2 in membrane re-organization and formation of the replication complex (19, 25) raise the possibility that NS1/2 determines persistence through changes in MNV replication. We found no evidence for an *in vitro* replication function of the NS1/2 persistence determinant in RAW264.7 cells (Fig. 4). However, its role in determining growth in the proximal colon during acute infection (Fig. 5D) means that NS1/2 may have functions specific to a
colonic cell type. Therefore, a role for NS1/2 in cell type-specific viral replication remains a possibility and identification of the colonic cell types in which MNV persists will be necessary to address this possibility experimentally.

While there are multiple potential mechanisms for persistence, all persistent viruses share the capacity to prevent clearance by the immune system. Strategies for preventing immune elimination include inhibition of antigen presentation or innate immune signaling, evasion of adaptive immunity through mutation of immune-dominant epitopes, and infection of an immune privileged site (30, 42, 57). Therefore, potential immune-modulatory functions of NS1/2 must also be considered in addition to basic replicative functions. Humoral immunity, cellular immunity, and innate immunity cooperate to clear infection with MNV1 (14, 15, 31), so NS1/2-mediated evasion of any of these immune components could account for its role in persistence. Identification of NS1/2 structures and interacting partners will be required to generate more detailed hypotheses about a role for NS1/2 in immune modulation.

Domains of NS1/2

The NS1/2 caspase cleavage sites (50) have been used by us and others (8) to define NS1/2 domains. The region 5’ of the caspase cleavage site, which contains the amino acid 94 persistence determinant, is poorly conserved among NoVs and is also poorly conserved within genogroups. The region 3’ of the caspase cleavage site, however, is conserved among NoVs and is bioinformatically predicted to fold into a permutated papain-like fold (1).
Characteristic of this fold, there are conserved cysteine, histidine, and histidine/asparagine residues predicted to form a catalytic triad. Supportive evidence for a catalytic function comes from a study of a picornaviral orthologue, where mutation of the conserved cysteine was found to block positive strand RNA synthesis in an in vitro replication system (46). Similarly, mutation of the conserved cysteine or histidine in MNV prevents recovery of plaquable virus from the reverse genetics system (TJN, data not shown). Whether the persistence determinant in the 5’ domain is related to a hypothetical catalytic function of the 3’ domain requires further biochemical and functional studies.

We find that the 5’ NS1/2 domain determines persistence and colonic growth of both CW3 and CR6 (Figs. 2E, 5D), but amino acid 94 determines persistence of CW3 only (Fig. 3B). This suggests that amino acid 94 interacts with CW3-specific sequences. The fact that the D94E mutation can increase colonic growth of both CW3 and CR6-5’ NS1/2 (CW3D94E, CR6-5’ NS1/2D94E, Fig. 5D), suggests that the CW3-specific interaction of amino acid 94 is within the 5’ domain. While these data do not preclude an additional role for strain-independent inter-genic interactions of the entire 5’ NS1/2 domain, they support the hypothesis that discreet domains exist within NS1/2. The separation of these domains by caspase 3 cleavage and the demonstrated induction of apoptosis during MNV infection (12, 50) raises the intriguing possibility that the MNV NS1/2 5’ domain acts independently of the 3’ domain to determine persistence and colonic tropism.
Acknowledgements

This work was supported by National Institutes of Health (NIH) grants to H.W.V. (AI0544483 and AI084887). T.J.N. was supported by an NIH training grant (5T32A100716334) and postdoctoral fellowships from the Cancer Research Institute and American Cancer Society. Washington University and H.W.V. receive income based on licenses for MNV technology. We thank members of the Virgin lab for their comments on the manuscript, P. Vachharajani for technical support, and D. Kreamalmeyer for managing mouse colonies.
Figure Legends

Figure 1. CW3 and CR6 differ in quantity and persistence of viral shedding in stool.

Stool was collected at the indicated days post-infection and genome copy number was determined by quantitative PCR. Data shows the mean shedding of at least four mice per time-point.

Figure 2. The 5' domain of NS1/2 is necessary and sufficient for persistence

A. Diagram of the MNV genome and the genomes of MNV chimeras used in B-E to map the persistence trait. B-E. Mice were inoculated with the indicated MNV strains. Stool was collected 35 days post-infection and MNV genomes were detected by quantitative PCR. B. Comparison of VP1-substituted strains. C. A screen of additional single-gene substitutions. D. Confirmation of CW3-NS1/2 persistence with three independent viral stocks. E. Comparison of NS1/2 domain substituted viruses. Data in C and D are from single experiments; B and E are combined from at least two experiments for each virus. 1/Ct = inverse of the threshold cycle.

Figure 3. An aspartic acid to glutamic acid change at position 94 of NS1/2 is sufficient for persistence.

A. Alignment of the first 117 amino acids of CW3 with CR6 and six additional persistent strains of MNV [accession numbers DQ223041, DQ223042,
DQ223043, EU004672, EU004673, and EU004677 (23, 55)]. Conserved amino acid residues are grey and non-conserved residues are black. The arrow indicates a unique aspartic acid residue at position 94 of CW3. B. Mice were inoculated with the indicated MNV strains. Stool was collected between 28 and 36 days post-infection and MNV genomes were detected by quantitative PCR. Data are combined from at least two experiments for each virus.

**Figure 4. Viral mutants with altered persistence phenotype have similar in vitro growth.** RAW264.7 cells were infected at an MOI of either 0.05 or 5 and viral growth was measured by plaque assay at the indicated times post-infection. Data are combined from three experiments.

**Figure 5. NS1/2 and amino acid 94 determine growth in the proximal colon, a major reservoir of persistent MNV.**

A-E. Tissues were harvested from MNV-infected mice and genome copy number was measured by quantitative PCR. A. Detection of CR6 in regions of the gastro-intestinal tract 35 days post-infection. Data are combined from two experiments for a total of five mice. B. A kinetic comparison of titers in spleen, proximal colon, and MLN following infection with either CW3 or CR6. Data are combined from three experiments for a total of nine mice per data point. C and D. Detection of the indicated viruses in tissues at day seven post-infection. Data are combined from at least two experiments for a total of at least eight mice for each data point.
CW3 and CR6 data from day seven in panel B is shown in panel C for reference.

E. Detection of CR6-VP1 in the indicated tissues at three or 35 days post-infection with $1 \times 10^6$ PFU. Data are combined from two experiments for a total of six mice per data point.
References


Asymptomatic rotavirus infections in England: prevalence, characteristics,
47. Schmid D., H.-W. Kuo, M. Hell, S. Kasper, I. Lederer, C. Mikula, B.
Springer, and F. Allerberger. 2011. Foodborne gastroenteritis outbreak in
an Austrian healthcare facility caused by asymptomatic, norovirus-
dendritic cells: master regulators of tolerance? Trends in Immunology
32:412–419.
norovirus Camberwell proteinase and cleavage of the N-terminal protein
50. Sosnovtsev S. V., G. Belliot, K.-O. Chang, V. G. Prikhodko, L. B.
2006. Cleavage map and proteolytic processing of the murine norovirus
and essential cleavage sites of the nonstructural polyprotein encoded by
ORF1 of the feline calicivirus genome. J. Virol. 76:7060–7072.
Protruding Domain of Capsid Protein is Necessary and Sufficient to
2010. Chronic shedders as reservoir for nosocomial transmission of
Henderson, and C. E. Wobus. 2012. Murine noroviruses (MNV) bind
glycolipid and glycoprotein attachment receptors in a strain-dependent
manner. J. Virol.
comprising a single genogroup exhibit biological diversity despite limited
Thackray, H. W. Virgin, and P. R. Lambden. 2007. Recovery of infectious
murine norovirus using pol II-driven expression of full-length cDNA.


A

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
</tr>
</thead>
<tbody>
<tr>
<td>MNV2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNV3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNV4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CW3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>41</th>
<th>50</th>
<th>60</th>
<th>70</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>MNV2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNV3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNV4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CW3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Day 28-36

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CW3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CW3 DME</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR6 E94D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CR6-5' NS1/2 DHE</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Log10 Genomes/Stool

n.s.